Skip to main content

Table 2 Changes in the number and percentage of CD4+ T cell lymphocytes.

From: CXCL10 blockade protects mice from cyclophosphamide-induced cystitis

Total CD4+ T cell Group Spleen Iliac lymph nodes Urinary bladder
Counts Control Ab-treated 24.2 × 106 ± 3.9 11.0 × 105 ± 0.9 1.49 × 104 ± 0.04
  Anti-CXCL10 Ab-treated 22.0 × 106 ± 3.1 16.4 × 105 ± 1.7 2.32 × 104 ± 0.2
  CYP- and control Ab-treated 0.6 × 106 ± 0.06* 0.1 × 105 ± 0.02 36.8 × 104 ± 4.6*
  CYP- and anti-CXCL10 Ab-treated 5.2 × 106 ± 0.6 1.1 × 105 ± 0.1* 22.9 × 104 ± 3.3*
Percentage Control Ab-treated 21.6 ± 1.3 39.3 ± 4.4 4.24 ± 0.23
  Anti-CXCL10 Ab-treated 20.8 ± 3.8 30.9 ± 3.2 16.3 ± 2.1*
  CYP- and control Ab-treated 2.4 ± 1.9 3.9 ± 0.19 50.5 ± 7.1
  CYP- and anti-CXCL10 Ab-treated 56.6 ± 6.5* 63.0 ± 7.2* 34.2 ± 3.7*
  1. Control or anti-mouse CXCL10 Abs solutions were administered beginning 2 days prior to CYP treatment and every 2 days thereafter. Five days after CYP administration, lymphocytes from the spleen, iliac lymph nodes, and urinary bladder were isolated, stained for CD3 and CD4 expression, and analyzed by flow cytometry. The studies were repeated three times, and the data presented are the mean of the number or percent change ± SEM (n = 10). Differences between experimental groups were considered significant when p < 0.01 (*).
\